Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)38.55
  • Today's Change0.05 / 0.13%
  • Shares traded309.50k
  • 1 Year change-9.19%
  • Beta0.6724
Data delayed at least 15 minutes, as of Nov 22 2024 01:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy11
Outperform17
Hold1
Sell0
Strong Sell0

Share price forecast in CNY

The 24 analysts offering 12 month price targets for Innovent Biologics Inc have a median target of 57.85, with a high estimate of 67.62 and a low estimate of 32.02. The median estimate represents a 50.25% increase from the last price of 38.50.
High75.6%67.62
Med50.2%57.85
Low-16.8%32.02

Earnings history & estimates in CNY

Innovent Biologics Inc reported annual 2023 losses of -0.66 per share on Mar 20, 2024.
Average growth rate-1.65%
More ▼

Revenue history & estimates in CNY

Innovent Biologics, Inc. had revenues for the full year 2023 of 6.21bn. This was 36.21% above the prior year's results.
Average growth rate+80.24%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.